GRAIL (NASDAQ:GRAL) Posts Earnings Results, Beats Estimates By $0.47 EPS

GRAIL (NASDAQ:GRAL) posted its earnings results on Tuesday. The company reported ($2.29) EPS for the quarter, topping the consensus estimate of ($2.76) by $0.47, Zacks reports. GRAIL had a negative net margin of 277.46% and a negative return on equity of 17.11%.

Here are the key takeaways from GRAIL’s conference call:

• GRAIL sold over 56,000 Galleri tests in Q1 (a 50% YoY increase) and reported screening revenue of $39.8M, citing expanding physician adoption and new health-system and employer partnerships.
• The FDA has accepted GRAIL’s PMA submission for review (PATHFINDER 2 and NHS-Galleri data plus a bridging analysis), but timing, the possibility of an advisory committee, and the ultimate outcome remain uncertain.
• The NHS-Galleri trial did not meet its combined primary endpoint (no significant reduction in combined stage 3+4), which could be viewed unfavorably by some stakeholders despite accompanying secondary benefits.
• Q1 non-GAAP results improved with adjusted gross profit of $19.7M, a narrower adjusted EBITDA loss (-$79.9M), a 12% smaller net loss, and cash of $823.1M to fund growth and milestones.
• Management reiterated 2026 revenue guidance (22–32%), plans a mid-year salesforce ramp and Epic/Quest/Athena integrations to ease provider ordering, but the pace of uptake from new digital and employer partners and ASP/mix effects are uncertain.

GRAIL Stock Performance

GRAIL stock traded down $1.26 during mid-day trading on Tuesday, reaching $54.40. 720,165 shares of the company’s stock were exchanged, compared to its average volume of 699,775. The business’s fifty day simple moving average is $50.40 and its 200 day simple moving average is $78.71. GRAIL has a one year low of $29.95 and a one year high of $118.84.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on GRAL shares. Piper Sandler assumed coverage on GRAIL in a research note on Friday, April 10th. They set a “neutral” rating and a $54.00 price target for the company. Canaccord Genuity Group dropped their target price on GRAIL from $105.00 to $80.00 and set a “buy” rating on the stock in a report on Friday, February 20th. TD Cowen upgraded GRAIL from a “hold” rating to a “buy” rating and set a $65.00 price target for the company in a report on Wednesday, March 18th. Wall Street Zen lowered GRAIL from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a research note on Tuesday, April 21st. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $68.63.

Insider Activity

In other news, President Joshua J. Ofman sold 61,665 shares of GRAIL stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total transaction of $3,078,316.80. Following the sale, the president directly owned 371,216 shares in the company, valued at $18,531,102.72. The trade was a 14.25% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Aaron Freidin sold 45,806 shares of the business’s stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total transaction of $2,286,635.52. Following the completion of the transaction, the chief financial officer directly owned 260,669 shares in the company, valued at $13,012,596.48. This trade represents a 14.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 310,267 shares of company stock valued at $15,485,396 in the last ninety days.

Institutional Trading of GRAIL

Several hedge funds have recently made changes to their positions in GRAL. Comerica Bank lifted its position in shares of GRAIL by 59.2% during the 3rd quarter. Comerica Bank now owns 465 shares of the company’s stock valued at $27,000 after buying an additional 173 shares during the last quarter. Intesa Sanpaolo S.p.A. bought a new stake in GRAIL in the 4th quarter valued at about $44,000. Ankerstar Wealth LLC purchased a new stake in GRAIL during the fourth quarter valued at about $45,000. Rossby Financial LCC lifted its holdings in GRAIL by 25.0% during the fourth quarter. Rossby Financial LCC now owns 1,250 shares of the company’s stock valued at $107,000 after purchasing an additional 250 shares during the last quarter. Finally, CIBC Private Wealth Group LLC boosted its position in GRAIL by 244.0% during the third quarter. CIBC Private Wealth Group LLC now owns 1,610 shares of the company’s stock worth $95,000 after purchasing an additional 1,142 shares during the period.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.